You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)與拜耳就一家位於德國的生物製劑工廠達成收購協議
格隆匯 01-17 09:36

原創:WuXi Biologic

這將成為藥明生物首個歐洲生物製劑廠,有力補充公司全球商業化生產能力; 藥明生物將作為拜耳公司產品科躍奇®的輔助生產服務商。

全球領先的開放式生物製藥技術平台公司藥明生物(WuXi Biologics, 2269.HK)和拜耳2020年1月16日共同宣佈達成一項協議,藥明生物將接管拜耳在德國勒沃庫森一家生物製劑工廠的運營工作、購買相關設備,以及該廠房所附的一項長期租賃合同。

根據商議中的生產合作協議,該工廠將由藥明生物負責運營,並作為拜耳公司產品科躍奇®(重組抗血友病因子)的輔助生產服務商。在滿足慣例成交條件的基礎上,此項交易計劃在未來幾個月內完成。相關財務細節未披露。

“我們很高興與拜耳簽署收購協議,以進一步快速提升公司高質量製劑生產能力。”藥明生物首席執行官陳智勝博士表示,“藥明生物近年來在歐盟、美國和中國三大市場的業務保持高速增長,此項收購進一步彰顯了公司持續踐行‘藥明生物提供全球雙廠生產戰略。藥明生物將不斷擴充生物製藥產能,通過公司健全強大的全球供應鏈網絡為客户提供高質量生物藥,造福廣大病患。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account